Diab Osama Ali, Helmy Mostafa, Gomaa Yasser, El-Shalakany Reem
From the Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Circ Cardiovasc Interv. 2017 Jan;10(1):e004348. doi: 10.1161/CIRCINTERVENTIONS.116.004348.
The incidence of contrast-induced acute kidney injury is strongly related to the amount of the given contrast. Our objectives were to evaluate the efficacy and safety of coronary sinus aspiration (CSA) procedure to reduce the volume of the given contrast and attenuate the risk of contrast-induced acute kidney injury.
The study included 43 patients with type 2 diabetes mellitus and renal impairment (creatinine 1.5-3 mg/dL) who were candidates for coronary angiography. Eighteen patients were subjected to CSA procedure during coronary angiography (CSA group), and 25 patients served as a control group. Periprocedural standard care was given. In CSA group, the coronary sinus was cannulated via subclavian or femoral venous approaches, and aspiration was done directly from a transseptal sheath (8 patients) or through a balloon occlusion catheter placed through the sheath (10 patients) simultaneously during each coronary injection. Estimated volume of aspirated contrast was calculated based on the percentage reduction in hematocrit value of the aspirate in relation to the patient's baseline hematocrit. Fraction of aspirated contrast was calculated by dividing estimated volume of aspirated contrast over the volume of injected contrast×100. Both study groups were matched in clinical and laboratory data, as well as volume of injected contrast. In CSA group, mean fraction of aspirated contrast was 39.35±10.47%. One patient in the CSA group, compared with 9 patients in the control group, developed contrast-induced acute kidney injury (P=0.028).
CSA during coronary angiography could effectively remove more than one third of the given contrast and may reduce the incidence of contrast-induced acute kidney injury in selected patients.
对比剂诱导的急性肾损伤的发生率与所用对比剂的量密切相关。我们的目的是评估冠状静脉窦抽吸(CSA)程序减少所用对比剂体积并降低对比剂诱导的急性肾损伤风险的有效性和安全性。
该研究纳入了43例2型糖尿病合并肾功能损害(肌酐1.5 - 3mg/dL)且适合进行冠状动脉造影的患者。18例患者在冠状动脉造影期间接受了CSA程序(CSA组),25例患者作为对照组。给予围手术期标准护理。在CSA组中,通过锁骨下或股静脉途径插入冠状静脉窦,并在每次冠状动脉注射时,直接从经房间隔鞘管(8例患者)或通过经鞘管放置的球囊闭塞导管(10例患者)进行抽吸。根据抽吸物血细胞比容值相对于患者基线血细胞比容的降低百分比计算估计的抽吸对比剂体积。通过将估计的抽吸对比剂体积除以注射对比剂体积×100来计算抽吸对比剂的比例。两个研究组在临床和实验室数据以及注射对比剂体积方面相匹配。在CSA组中,抽吸对比剂的平均比例为39.35±10.47%。CSA组有1例患者发生对比剂诱导的急性肾损伤,而对照组有9例患者发生(P = 0.028)。
冠状动脉造影期间的CSA可有效清除超过三分之一的所用对比剂,并可能降低特定患者中对比剂诱导的急性肾损伤的发生率。